Radiotherapy in
adrenocortical carcinoma
Buelent Polat, Martin Fassnacht, Leo Pfreundner, Matthias
Guckenberger,
Cancer 2009; Volume 115 Issue
13, Pages 2816 - 2823
Adrenocortical carcinoma (ACC) is a rare malignancy, and patients
with ACC have a poor prognosis. Even after radical surgery, up to
85% of patients develop recurrent disease. Systemic treatment
options still have limited efficacy. Because the role of
radiotherapy is not defined well and because ACC often is considered
radioresistant, the authors reviewed the available data on
radiotherapy for ACC.
Original articles and reviews were identified using a PubMed search
strategy that included the period up to July 2008. Ten articles were
identified that covered radiotherapy in a total of 129 patients with
ACC (64 patients received postoperative irradiation, and 65 patients
received palliative therapy for advanced disease). In addition, 26
patients were identified in the German ACC Registry who received
palliative radiotherapy. Furthermore, patterns of failure after
adjuvant radiotherapy were investigated, and the authors provided
recommendations for patient selection, treatment planning, and
treatment protocols.
In an adjuvant setting,
postoperative radiotherapy was able to prevent local recurrence in
the majority of patients. In those with
advanced disease, a response
to radiotherapy was observed in 57% of patients who received
palliative radiotherapy. Therefore, the authors concluded
that radiotherapy may play an important role in the care of patients
with ACC.
Until better evidence is available, the authors recommended the
following approach: Adjuvant radiotherapy to the tumor bed
should be considered in patients at high risk for local recurrence (eg,
incomplete/R1 resection); a total dose of >40 grays (Gy) with single
fractions of 1.8 Gy to 2 Gy should be administered (including a
boost volume to reach from 50 Gy to 60 Gy in individual patients);
and radiotherapy in a palliative setting may be used for symptomatic
metastases to bone, brain, or vena cava obstruction. With
state-of-the-art technology, acute and long-term toxicities mostly
were mild to moderate. However, the authors concluded that
prospective investigations would be required to fully define the
therapeutic potential of this important treatment option. |